Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ENSPRYNG safely and effectively. See full prescribing information for ENSPRYNG. ENSPRYNG® (satralizumab-mwge) injection, for subcutaneous use Initial U.S. Approval: 2020
Medication labelWhy this: Advisory · dailymed-prescription
ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
- generic_name
- satralizumab
- product_names
- Satralizumab
- ndc
- 50242-007, 50242-007-01, 50242-007-86, 50242-007-55, 50242-007-33
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en